2023-07-10T09:11:54-05:00 2022-12-31 630721243 BORLAND BENEFIELD PC 800 SHADES CREEK PKWY STE 875 BIRMINGHAM AL 35209 990 2022-01-01 631034376 VISTAR INC VIST 2059338101 700 SOUTH 19TH STREET BIRMINGHAM AL 35233 LOUIS DELL'ITALIA MD PRESIDENT 2059338101 2023-06-12 1 LOUIS DELLITALIA MD 999009999 0 JEFFREY D CHANDLER P00764759 2058027212 2023-05-25 3 AAL1 IAL1 2022 2023-04-26 12:10:37Z LOUIS DELL'ITALIA MD 700 SOUTH 19TH STREET BIRMINGHAM AL 35233 477014 0 X WWW.VISTARINC.ORG X 1990 AL THE MISSION OF VISTAR, INC. IS TO ADVANCE THE RESEARCH AND EDUCATION MISSIONS OF THE DEPARTMENT OF VETERANS AFFAIRS BY PROVIDING A FLEXIBLE MECHANISM FOR THE RECEIPT AND ADMINISTRATION OF FUNDS, OTHER THAN VA APPROPRIATIONS, FOR THE CONDUCT OF APPROVED VA RESEARCH AND EDUCATION ACTIVITIES. 6 2 7 6 0 0 0 0 388639 476990 15 24 0 0 388654 477014 0 0 0 0 289868 252422 0 0 0 106131 217598 395999 470020 -7345 6994 478660 611679 89918 215943 388742 395736 X THE MISSION OF VISTAR, INC. IS TO ADVANCE THE RESEARCH AND EDUCATION MISSIONS OF THE DEPARTMENT OF VETERANS AFFAIRS BY PROVIDING A FLEXIBLE MECHANISM FOR THE RECEIPT AND ADMINISTRATION OF FUNDS, OTHER THAN VA APPROPRIATIONS, FOR THE CONDUCT OF APPROVED VA RESEARCH AND EDUCATION ACTIVITIES. 0 0 384026 476990 RESEARCH PROJECTSCALLAWAY; PREEMPT CRCPREVENTION OF COLORECTAL CANCER THROUGH A MULTIOMICS BLOOD TESTING.COOPER; INSIGHT COPDINTERVENTION STUDY IN OVERWEIGHT PATIENTS WITH COPD. COOPER; LABA/LAMA/ICSA 24-WEEK MULTI-CENTER, DOUBLE-BLIND, PLACEBO CONTROLLED DOSE-RANGE FINDING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ORAL QBW251 IN COPD PATIENTS ON TRIPLE INHALED THERAPY.DAS; PHASE II STUDYA PHASE II OPEN-LABEL, PARALLEL GROUP STUDY OF ABIRATERONE ACETATE PLUS PREDNISONE IN AFRICAN AMERICAN AND CAUCASIAN MEN WITH METASTATIC CASTRATE-RESISTANT PROSTATE CANCER.DAS; N-CCAPSNCI COVID-19 IN CANCER PATIENTS STUDY: A LONGITUDINAL NATURAL HISTORY STUDYDAS; NEOADAURAA PHASE III, RANDOMISED, CONTROLLED, MULTI-CENTRE, 3-ARM STUDY OF NEOADJUVANT OSIMERTINIB AS MONOTHERAPY OR IN COMBINATION WITH CHEMOTHERAPY VERSUS STANDARD OF CARE CHEMOTHERAPY ALONE FOR THE TREATMENT OF PATIENTS WITH EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION POSITIVE, RESECTABLE NON-SMALL CELL LUNG CANCER.DELL'ITALIA; PHASE III STUDY TO ASSESS THE EFFICACY OF AD26.COV2.S FOR THE PREVENTION OF SARS-COV-2-MEDIATED COVID-19 IN ADULTS AGED 18 AND OLDER.DELL'ITALIA; PHASER: PHARMACOGENOMIC TESTING FOR VETERANSHAGE; PROMINENT - PEMAFIBRATE TO REDUCE CARDIOVASCULAR OUTCOMES BY REDUCING TRIGLYCERIDES IN PATIENTS WITH DIABETESMARKLAND; PRAGMATIC EVALUATION OF EVENTS AND BENEFITS OF LIPID-LOWERING IN OLDER ADULTS (PREVENTABLE) TRIALWELLS; A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LIQUID ALPHA1-PROTEINASE INHIBITOR (HUMAN) PLUS STANDARD MEDICAL TREATMENT (SMT) VERSUS PLACEBO PLUS SMT IN HOSPITALIZED SUBJECTS WITH COVID-19 384026 1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 8 0 1 7 0 0 0 0 0 0 0 0 0 0 0 X 6 2 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 0 0 AL X LOUIS DELL'ITALIA MD 2059338101 700 SOUTH 19TH STREET BIRMINGHAM AL 35233 LOUIS J DELL'ITALIA MD PRESIDENT 4.00 40.00 X X 0 0 0 J ALLEN COOPER MD VICE PRESIDENT 1.00 40.00 X X 0 0 0 SUSAN LAING PHD TREASURER 1.00 40.00 X X 0 0 0 PAUL W SANDERS MD SECRETARY 1.00 40.00 X X 0 0 0 OLADIPO A KUKOYI MD COMMUNITY MEMBER 1.00 40.00 X 0 0 0 ANDREW SELLERS COMMUNITY MEMBER 1.00 40.00 X 0 0 0 DINA AVERY EXECUTIVE DIRECTOR 40.00 0.00 X 35164 0 1764 35164 0 1764 0 0 0 0 0 RESTRICTED GOVERNMENT 900099 381569 381569 RESTRICTED GOVERNMENT 900099 69125 69125 UNRESTRICTED NON-GOVER 900099 13670 13670 NON-GOVERNMENT CLINICA 900099 12621 12621 OTHER REVENUE 900099 5 5 476990 24 24 477014 476990 0 24 35164 35164 188456 188676 -220 6922 4877 2045 21880 17026 4854 435 435 18054 18054 6337 6337 4500 4500 3932 1908 2024 3246 3246 825 825 3005 3005 2855 2855 SUBCONTRACTORS 161734 161734 RESEARCH STIPENDS 9370 9370 DUES AND SUBSCRIPTIONS 1800 1800 PERMITS, FEES, AND TAXE 1505 1505 470020 384026 85994 0 220591 126040 92853 110251 152438 364281 1257 2592 15027 6512 11521 8515 478660 611679 89918 215943 89918 215943 X 39404 1088 349338 394648 388742 395736 478660 611679 6994 0 X 1 X 0 0 0 X VETERANS ADMINISTRATION MEDICAL CENTER BIRMINGHAM AL 15027 6512 8515 8515 X PART X, LINE 2: THE ORGANIZATION IS EXEMPT FROM FEDERAL INCOME TAXES BY THE INTERNAL REVENUE SERVICE UNDER SECTION 501 (C) (3) OF THE INTERNAL REVENUE CODE. THE ORGANIZATION HAD NO UNCERTAIN TAX POSITIONS THAT QUALIFY FOR DISCLOSURE IN THE FINANCIAL STATEMENTS. THE ORGANIZATION HAS FILED AN ANNUAL FORM 990 WITH THE INTERNAL REVENUE SERVICE, AND ITS RETURNS FOR THE YEAR ENDED 2019 AND SUBSEQUENT RETURNS REMAIN SUBJECT TO EXAMINATION BY TAX AUTHORITIES. FORM 990, PART VI, SECTION B, LINE 11B FORM 990 IS REVIEWED BY EXECUTIVE DIRECTOR AND APPROVED BY THE BOARD OF DIRECTORS FORM 990, PART VI, SECTION B, LINE 12C ENFORCEMENT OF CONFLICTS POLICY UTILITIZE AND RELY ON VETERANS HOSPITAL CONFLICT OF INTEREST POLICY FORM 990, PART VI, SECTION B, LINE 15A THE BOARD OF DIRECTORS APPROVE THE EXECUTIVE DIRECTOR'S SALARY ANNUALLY. FORM 990, PART VI, SECTION C, LINE 19 DOCUMENTS MADE AVAILABLE UPON REQUEST VETERAN ADMINISTRATION 700 S 19TH STREET BIRMINGHAM AL 35233 631034376 AL 501(C)(27) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0